A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, ...

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample ...

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.